Psoriasis and obesity travel together, and the association is not incidental. Genetic evidence puts weight upstream of the disease rather than beside it, dermatologists have recommended weight loss for years, and the arrival of a drug class that reliably removes fifteen to twenty percent of body weight was always going to be tested on this skin.
It has now been tested, once, at scale. What that trial measured is not quite what its headline says, and the four other randomized records in this class enrolled 76 people between them and point in two directions. Cutaneous side effects of the drugs themselves are a separate subject, covered in the skin reactions article, and the weight figures the class is sold on are in the tirzepatide weight-loss article.
The one large trial, and the endpoint it was built on
A phase 3b, randomized, open-label, 52-week trial ran at 72 US sites in adults with moderate to severe plaque psoriasis who had overweight with a weight-related comorbidity or obesity. Participants were randomized 1:1 to ixekizumab plus tirzepatide or ixekizumab alone, with diet and exercise counseling in both arms. Ixekizumab’s own label describes it as a humanized interleukin-17A antagonist indicated for moderate-to-severe plaque psoriasis and for active psoriatic arthritis, so everyone in the trial was already receiving an approved psoriasis biologic; the randomization was over whether tirzepatide was added on top of it.[1]
Among 274 randomized participants — mean age 45.6, mean body-mass index 39.2, mean psoriasis duration 14.6 years, mean PASI 19.7 — 84.3% completed through the week-36 primary endpoint. That endpoint was simultaneous achievement of PASI 100 and a weight reduction of 10% or more, and it was met by 27.1% against 5.8%, a risk difference of 21.2 points (95% CI 12.8 to 29.7, P < .001).[1]
A composite endpoint containing weight loss, in a trial where one arm gets a weight-loss drug, is guaranteed to separate. The number that answers the dermatological question is the key secondary: PASI 100 alone, 40.6% against 29.0%, a risk difference of 11.6 points with a 95% CI of 0.3 to 22.9 and P = .04. A confidence interval whose lower bound is three tenths of a percentage point, in an unblinded trial scoring a visually assessed skin index, is the honest version of this result. It is a positive finding and it is a fragile one. (A published correction to that paper addresses errors in one of its tables; every figure quoted here is a primary or key secondary endpoint as the trial reported it.)
Gastrointestinal events occurred more frequently in the combination arm, which is the expected pattern for this class and is set out in what the trials recorded on side effects. Nothing in the trial tells you what tirzepatide does to psoriasis on its own, because no arm took it without a biologic.
Before that trial, the whole randomized record was 76 people
Three randomized studies of this class in psoriasis preceded it, and the only one that used a placebo found nothing. Twenty obese, glucose-tolerant patients with plaque psoriasis and a PASI of at least 8 were randomized 1:1 to liraglutide or placebo for eight weeks. PASI changed by −2.6 ± 2.1 on liraglutide against −1.3 ± 2.4 on placebo (P = 0.228). The quality of life index did not separate either (P = 0.564), nor did high-sensitivity C-reactive protein (P = 0.992). Weight fell 4.7 kg against 1.6 kg (P = 0.014), and transient nausea occurred in 45% of the liraglutide group and none of the placebo group.[2]
The two positive studies are both open-label and both in people with type 2 diabetes. In one, 25 patients were randomized to liraglutide or a control group for 12 weeks; the dermatology life quality index in the treatment arm fell from 22.00 ± 5.85 to 3.82 ± 3.60, and skin expression of interleukin-17, interleukin-23 and tumor necrosis factor alpha improved.[3] In the other, 31 psoriatic patients with type 2 diabetes on metformin were randomized to semaglutide (n = 15) or control (n = 16) for 12 weeks; median PASI fell from 21 to 10 (P = 0.002) and the median quality-of-life score from 14 to 4 (P = 0.002), with significant falls in interleukin-6 and C-reactive protein.[4]
Three small trials, three different molecules, three different control conditions, and the one that blinded participants against a placebo is the one that found no effect. A scoping review of this class across inflammatory arthritis and psoriasis found 19 studies, of which 13 concerned psoriasis — two randomized trials, four case reports, three longitudinal cohorts and the rest basic science — and named the recurring limitations plainly: small samples, short follow-up and absent control groups.[5]
Weight is genuinely upstream of psoriasis
The strongest claim on this page is not about the drug. A mendelian randomization study used 97 genetic variants as an instrument for body-mass index across 396,495 individuals in one sample and 356,926 in another. Observationally, psoriasis cases carried a mean body-mass index 1.26 kg/m² higher than controls in adults and 1.55 kg/m² higher in children, and each 1 kg/m² was associated with 4% higher odds of psoriasis. The genetic estimate was larger: a 1 kg/m² increase in genetically determined body-mass index raised the odds of psoriasis by 9% (OR 1.09, 95% CI 1.06 to 1.12, P = 4.67 × 10⁻⁹), with no evidence of a reverse effect of psoriasis genetic risk on weight.[6]
That is a causal direction, established without any drug at all, and it is the reason weight loss belongs in a psoriasis conversation. It does not follow that a particular intervention delivers a particular skin result, which is what the next two trials were built to check.
Losing weight without a GLP-1 has been randomized twice, with different answers
Sixty overweight patients with psoriasis were randomized to a low-energy diet of 800 to 1,000 kcal a day for eight weeks, then a reintroduction phase, against ordinary healthy eating. At week 16 the intervention group had lost 15.4 kg more (95% CI 12.3 to 18.5, P < .001). The mean difference in PASI was −2.0 and did not reach significance (P = .06), while the quality-of-life index did, at −2.0 (95% CI −3.6 to −0.3, P = .02).[7] Fifteen kilograms of separation, and the skin score missed.
The larger trial reached the opposite conclusion. 303 overweight or obese patients with moderate-to-severe plaque psoriasis who had not cleared after four weeks of systemic treatment were randomized to a 20-week dietary plan with exercise or to counseling alone. Median PASI reduction was 48% (95% CI 33.3 to 58.3) against 25.5% (95% CI 18.2 to 33.3), P = 0.02, and a PASI 50 response was reached by 49.7% against 34.2% (P = 0.006). Only 29.8% of the intervention arm actually reached the 5% weight-loss target, against 14.5% of controls.[8]
The two trials differ in size, duration, baseline severity and whether participants were already on systemic therapy. Read together they suggest that weight loss helps psoriasis in the setting where the larger one ran — on top of a systemic drug that had not finished the job — which is also the setting the phase 3b trial chose.
The finding that runs the other way
One large analysis points in a direction no seller will mention. Using a federated US network, investigators emulated an active-comparator trial: adults with type 2 diabetes starting a GLP-1 receptor agonist or a DPP-4 inhibitor between 2018 and 2022, prior users of either class excluded, outcomes in the first three months discarded to address protopathic bias, and 169,630 matched pairs followed up to four years.
Against DPP-4 inhibitors, GLP-1 initiation was associated with a higher risk of incident psoriasis (HR 1.19, 95% CI 1.11 to 1.28) and lower risks of pemphigus (HR 0.32, 95% CI 0.16 to 0.63) and bullous pemphigoid (HR 0.61, 95% CI 0.43 to 0.87). No other autoimmune or inflammatory skin outcome differed after correction for multiple testing, and the findings persisted across subgroup and sensitivity analyses.[9] It is a database emulation rather than a trial, its comparator is another diabetes drug rather than nothing, and new diagnoses in a population under closer medical observation are always suspect. It is also the largest piece of evidence anyone has on whether this class provokes psoriasis, and it does not say no.
Psoriatic arthritis has a completed trial and no published result
Psoriatic disease is skin and joints, and the joints are the emptier half. The scoping review above recorded that no psoriasis study it found reported on psoriatic arthritis outcomes at all.[5] A 2025 scoping review of this class specifically in psoriatic disease reaches for the same rationale — shared Th1 and Th17 signaling, obesity worsening severity and treatment resistance — and concludes that further clinical trials are warranted to define any role at all.[10]
The public registry holds 15 interventional and observational studies crossing psoriasis with these molecules and six crossing psoriatic arthritis, against 606 for obesity in the identical query. One of the psoriatic arthritis entries is a 279-participant trial of ixekizumab with tirzepatide that completed in November 2025 and has posted no results. Until it does, the joint question is open. What is known about combining these drugs with biologic therapy generally sits in the immunosuppressants article.
What a buyer is actually holding
No GLP-1 receptor agonist carries a psoriasis indication from any regulator, and the labels do not mention the disease: across the full structured product labeling for Wegovy, Zepbound and Mounjaro, the strings psoriasis and psoriatic appear zero times in 212,786, 154,687 and 142,530 characters of extracted text, in documents where gastric emptying appears seven to eight times. Silence is neither permission nor prohibition, and it means a prescriber has nothing labeled to work from.
The trial that produced the 11.6-point result also gave every participant a biologic that costs more than the injection and requires a dermatologist to prescribe. A cash-pay vial delivers the molecule and none of the rest, and most of these sellers dispense compounded semaglutide or tirzepatide, which the FDA does not review for safety, effectiveness or quality before shipping — the distinction is in what not FDA-approved actually means, and the sellers are collected on the compounded tirzepatide board.
The defensible summary is short. Adding tirzepatide to a biologic produced 11.6 percentage points more complete skin clearance at week 36 in an open-label trial of 274 people, on a confidence interval that nearly touched zero. Before it, the only placebo-controlled trial in this class found no effect on psoriasis in eight weeks. Weight is causally upstream of the disease, dietary weight loss has helped in one randomized trial and missed in another, and a matched cohort of 169,630 pairs recorded more new psoriasis on this class rather than less. None of that is a reason to buy a vial for your skin, and none of it replaces a dermatologist.